ENDRA Life Sciences Overview
Latest ROE for ENDRA Life Sciences: -93.77% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-93.77%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for NDRA is -93.77%. That is below the Technology sector average of 47.48%. Investors often review this figure alongside ENDRA Life Sciences's historical trend and sector peers before judging valuation or financial health.
Against Technology companies, NDRA currently prints -93.77% for ROE, while the sector average sits near 47.48%. That is roughly 297.5% below the sector mean. Large gaps often invite a closer look at ENDRA Life Sciences's growth, margins, and balance sheet.
Return on Equity shows how effectively ENDRA Life Sciences converts resources into returns. At -93.77%, NDRA may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting NDRA's ROE (-93.77%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack ENDRA Life Sciences's ROE against similar Technology names. You can also browse sector and industry screens on Stockcircle for a broader set of Technology companies and their key multiples and fundamentals.
